Prof. Dr. med. Peter Sinn

Medical Schools, Universities of Erlangen and TU Munich, Germany

MD-Thesis (magna cum laude), Univ. of Erlangen

Licensure (Approbation) in Medicine, TU Munich

Board Certification in Pathology

PhD Degree (Habilitation)

Resident, Dept. of Pathology Univ. of Marburg

Postdoctoral Research Fellowship (DFG) Dept. of Pathology

Resident, Dept. of Pathology University of Heidelberg

Consultant (Oberarzt), Dept. of Pathology University of Heidelberg

Head, Division of Gynecopathology, Univ. Hospital, Heidelberg

Associate Professor of Pathology (apl. Prof.) Univ. of Heidelberg

Posterpreis der Dt. Ges. f. Senologie (DGS)

Posterpreis der International Society for the Study of Vulvovaginal Disease (ISSVD)

Posterpreis der Dt. Ges. f. Senologie (DGS)

Member, German Society of Pathology (DGP)
Member, European Society of Pathology (ESP)
Member, International Academy of Pathology (IAP), German Division
Member, Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO)
Member, German Society of Senology (DGS)
Member, German Cancer Society (DKG)
Fellow, International Society for the Study of Vulvovaginal Disease (ISSVD)

Member, AGO Organkommission Mamma
Member, Interdisciplinary S3 guideline committee breast cancer
Member, Educational Committee of the IAP, German Division

Molecular and translational pathology of the breast and female genital tract. Digital pathology in education and research

1. Gutjahr E, Streng A, Aulmann S, Flechtenmacher C, Toberer F, Heil J, Böcker W, Sinn P. Pathologie der Mamillenregion : Teil II: Tumoren, tumorartige Läsionen und Überschussbildungen. Der Pathologe. 4 ed. Springer Medizin; 2020 May 26;51(10):e203–8. PMID: 32458047
2. Streng A, Gutjahr E, Aulmann S, Flechtenmacher C, Toberer F, Heil J, Böcker W, Sinn P. Pathologie der Mamillenregion : I. Morbus Paget der Mamille, Varianten und Differenzialdiagnosen. Der Pathologe. 3rd ed. 2020 May 13;29(4):14–399. PMID: 32405655
3. Heil J, Pfob A, Kuerer HM. De-escalation towards omission is the tipping point of individualizing breast cancer surgery. Eur J Surg Oncol. 2020 Mar 19. PMID: 32241595
4. Golatta M, Vrancken Peeters MJ. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol. 2020 Jan;31(1):61–71. PMID: 31912797
5. Klebe M, Fremd C, Kriegsmann M, Kriegsmann K, Albrecht T, Thewes V, Kirchner M, Charoentong P, Volk N, Haag J, Wirtz R, Oskarsson T, Schulz A, Heil J, Schneeweiss A, Winter H, Sinn P. Frequent Molecular Subtype Switching and Gene Expression Alterations in Lung and Pleural Metastasis From Luminal A-Type Breast Cancer. JCO Precision Oncology. 2020;4:848–859. PMCID: PMC7446514
6. Heil J, Pfob A, Sinn P, Rauch G, Bach P, Thomas B, Schaefgen B, Kuemmel S, Reimer T, Hahn M, Thill M, Blohmer J-U, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Ditsch N, Rody A, Große R, van Mackelenbergh M, Reinisch M, Karsten M, Golatta M. Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy. Ann Surg. 2020;Publish Ahead of Print.
7. Rüschoff J, Lebeau A, Sinn P, Schildhaus H-U, Decker T, Ammann J, Künzel C, Koch W, Untch M. Statistical modelling of HER2-positivity in breast cancer: Final analyses from two large, multicentre, non-interventional studies in Germany. Breast. 2019 Dec 18;49:246–253. PMID: 31918324
8. Funk A, Heil J, Harcos A, Gomez C, Stieber A, Junkermann H, Hennigs A, Rauch G, Sinn HP, Riedel F, Schäfgen B, Hug S, Maier A, Blumenstein M, Domschke C, Schott S, Wallwiener M, Rom J, Schütz F, Sohn C, Golatta M. Efficacy of intraoperative specimen radiography as margin assessment tool in breast conserving surgery. Breast Cancer Res Treat. 7 ed. 2019 Oct 25;347(16):1233. PMID: 31654190
9. Glaeser A, Sinn P, Garcia-Etienne C, Riedel F, Hug S, Schaefgen B, Golatta M, Hennigs A, Feisst M, Sohn C, Heil J. Heterogeneous Responses of Axillary Lymph Node Metastases to Neoadjuvant Chemotherapy are Common and Depend on Breast Cancer Subtype. Ann Surg Oncol. Springer International Publishing; 2019 Oct 11;116(12):2884–9. PMID: 31605339
10. Varga Z, Sinn P, Seidman A. Author's reply to: Comparing the performance of gene expression assays in breast cancer. Int J Cancer. 2019 Aug 15;145(4):1163–1164. PMID: 30895601
11. Varga Z, Sinn P, Seidman A. Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer. Int J Cancer. 2019 Aug 15;145(4):882–893. PMID: 30653259
12. Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert U-S, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe H-H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn P, Solbach C, Solomayer E-F, Stickeler E, Thomssen C, Wenz F, Witzel I, Wöckel A. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care. 2019 Aug;14(4):224–245. PMCID: PMC6751475
13. Thill M, Jackisch C, Janni W, Müller V, Albert U-S, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Kolberg-Liedtke C, Kreipe H-H, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn P, Solbach C, Solomayer E-F, Stickeler E, Thomssen C, Untch M, Wenz F, Witzel I, Wöckel A, Ditsch N. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care. 2019 Aug;14(4):247–255. PMCID: PMC6751428
14. Kriegsmann M, Gomez C, Heil J, Schäfgen B, Gutjahr E, Kommoss FKF, Kriegsmann K, Flechtenmacher C, Goeppert B, Sinn P. IgG4-related sclerosing mastitis in a 49-year-old patient with multiple, tumor-like nodules-Diagnostic accuracy of core needle biopsy. Breast Journal. 2019 Jul 6;366(6):539–1253. PMID: 31280490
15. Stefanovic S, Deutsch TM, Wirtz R, Hartkopf A, Sinn P, Schuetz F, Sohn C, Bohlmann MK, Sütterlin M, Schneeweiss A, Wallwiener M. Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells. Cancers (Basel). 2019 Mar 11;11(3). PMCID: PMC6468370
16. Fremd C, Hlevnjak M, Zapatka M, Zoernig I, Halama N, Fejzibegovic N, Thewes V, Lichter P, Schirmacher P, Kloor M, Marme F, Schütz F, Kosaloglu Z, Sinn P, Jäger D, Schneeweiss A. Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care. 2019 Mar;14(1):53–59. PMCID: PMC6465703
17. Lebeau A, Denkert C, Sinn P, Schmidt M, Wöckel A. Update der S3-Leitlinie Mammakarzinom : Was gibt es Neues für Pathologen? Der Pathologe. Springer Medizin; 2019 Mar;40(2):185–198. PMID: 30847505
18. Vogt PH, Besikoglu B, Bettendorf M, Frank-Herrmann P, Zimmer J, Bender U, Knauer-Fischer S, Choukair D, Sinn P, Lau Y-FC, Heidemann PH, Strowitzki T. Gonadoblastoma Y locus genes expressed in germ cells of individuals with dysgenetic gonads and a Y chromosome in their karyotypes include DDX3Y and TSPY. Hum Reprod. 2019 Feb 12;34(4):770–779. PMID: 30753444
19. Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marme F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A. Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer. Breast Cancer Res Treat. 2019 Jan;173(1):155–165. PMID: 30276763
20. Thoeni C, Holzer K, Leichsenring J, Porcel C, Straub BK, Sinn HP, Elsaesser M, Volckmar AL, Schirmacher P, Waldherr R, Lasitschka F. Renal Tubular Dysgenesis in a Case of Fetus Acardius Amorphus. Case Reports in Pathology. 2019;2019:5416936. PMCID: PMC6875321
21. Heil J, Richter H, Golatta M, Sinn P. Vacuum-Assisted Biopsy to Diagnose a Pathological Complete Response in Breast Cancer Patients After Neoadjuvant Systemic Therapy. Ann Surg. 2018 Dec;268(6):e60–e61. PMID: 29064903
22. Heil J, Sinn P, Richter H, Pfob A, Schaefgen B, Hennigs A, Riedel F, Thomas B, Thill M, Hahn M, Blohmer J-U, Kuemmel S, Karsten MM, Reinisch M, Hackmann J, Reimer T, Rauch G, Golatta M. RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial. BMC Cancer. BioMed Central; 2018 Aug 25;18(1):851. PMCID: PMC6109284
23. Abubakar M, Chang-Claude J, Ali HR, Chatterjee N, Coulson P, Daley F, Blows F, Benitez J, Milne RL, Brenner H, Stegmaier C, Mannermaa A, Rudolph A, Sinn P, Couch FJ, Devilee P, Tollenaar RAEM, Seynaeve C, Figueroa J, Lissowska J, Hewitt S, Hooning MJ, Hollestelle A, Foekens R, Koppert LB, investigators K, Bolla MK, Wang Q, Jones ME, Schoemaker MJ, Keeman R, Easton DF, Swerdlow AJ, Sherman ME, Schmidt MK, Pharoah PD, García-Closas M. Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. Int J Cancer. John Wiley & Sons, Ltd; 2018 Aug 15;143(4):746–757. PMCID: PMC6041155
24. Polycarpou-Schwarz M, Groß M, Mestdagh P, Schott J, Grund SE, Hildenbrand C, Rom J, Aulmann S, Sinn P, Vandesompele J, Diederichs S. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene. Nature Publishing Group; 2018 Aug;37(34):4750–4768. PMID: 29765154
25. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi J-I, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, Deimling von A. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathol. 4 ed. Springer Berlin Heidelberg; 2018 Jul;136(1):153–166. PMID: 29687258
26. Thill M, Liedtke C, Müller V, Janni W, Schmidt M, AGO Breast Committee. AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018. Breast Care. 2018 Jul;13(3):209–215. PMCID: PMC6062660
27. Riedel F, Sellner L, Harcos A, Sinn H, Hennigs A, Golatta M, Heil J, Mayer L. Aggressives B-Zell-Non-Hodgkin-Lymphom der Mamma bei einer 77-jährigen Patientin. TumorDiagn u Ther. © Georg Thieme Verlag KG; 2018 May 14;39(04):239–242.
28. Pfitzner BM, Lederer B, Lindner J, Solbach C, Engels K, Rezai M, Dohnal K, Tesch H, Hansmann ML, Salat C, Beer M, Schneeweiss A, Sinn P, Bánkfalvi A, Darb-Esfahani S, Minckwitz von G, Sinn BV, Kronenwett R, Weber K, Denkert C, Loibl S. Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years. Mod Pathol. 2018 Apr;31(4):607–615. PMID: 29271415
29. Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran F-A, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubinski J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Głaz A, Chenevix-Trench G, Cazorla A, Brucker SY, Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Hogdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benitez J, Pharoah PDP, Köbel M, Ramus SJ, Goode EL. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. 2018 Mar;93(3):307–320. PMCID: PMC5870793
30. Denkert C, Minckwitz von G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer J-U, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018 Jan;19(1):40–50. PMID: 29233559
31. Bartosova M, Schaefer B, Bermejo JL, Tarantino S, Lasitschka F, Macher-Goeppinger S, Sinn P, Warady BA, Zaloszyc A, Parapatics K, Májek P, Bennett KL, Oh J, Aufricht C, Schaefer F, Kratochwill K, Schmitt CP. Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy. J Am Soc Nephrol. 2018 Jan;29(1):268–282. PMCID: PMC5748916
32. Jauch SF, Riethdorf S, Sprick MR, Schutz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marme F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A. Zur prognostischen Relevanz des CTC-Status bei Progress des metastasierten Mammakarzinoms. Senologie. 2018. p. 136–137.
33. Heublein S, Braun E, Schulz A, Fremd C, Kirchner M, Jäger D, Sohn C, Sinn P, Schneeweiss A. Molekulare Prädiktoren zur Abschätzung des Therapieansprechens von Patientinnen mit frühem triple-negativen Mammakarzinom. Geburtsh Frauenheilkd. 2018. p. FV30.
34. Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran F-A, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna D, Staebler A, Karlan BY, Gilks B, Bowtell DD, Hogdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benitez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PD, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017 Dec 1;3(12):e173290. PMCID: PMC5744673
35. Sinn P, Schneeweiss A, Endris V, Penzel R, Schirmacher P, Stenzinger A. Intrinsic subtypes and risk scores in ER+/HER2-Breast Cancer: a comparison of Prosigna and OncotypeDX risk categories with Ki67. Der Pathologe. 2017. p. 540.
36. Varga Z, Sinn P, McCullough D, Lau A, Stöppler MC, Baehner FL, Chao C, Seidman A. 187PSummary of head-to-head comparisons of patient (pt) risk classifications by the 21-gene recurrence score (RS) assay and other genomic assays for early breast cancer (EBC). Ann Oncol [Internet]. Oxford University Press; 2017 Sep 1;28(suppl_5):57. Available from: academic.oup.com/annonc/article/doi/10.1093/annonc/mdx362.037/4108354
37. Stefanovic S, Wirtz R, Deutsch TM, Hartkopf A, Sinn P, Varga Z, Sobottka B, Sotiris L, Taran F-A, Domschke C, Hennigs A, Brucker SY, Sohn C, Schuetz F, Schneeweiss A, Wallwiener M. Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry. Oncotarget. 2017 Aug 1;8(31):51416–51428. PMCID: PMC5584258
38. Thewes V, Simon R, Hlevnjak M, Schlotter M, Schroeter P, Schmidt K, Wu Y, Anzeneder T, Wang W, Windisch P, Kirchgäßner M, Melling N, Kneisel N, Büttner R, Deuschle U, Sinn HP, Schneeweiss A, Heck S, Kaulfuss S, Hess-Stumpp H, Okun JG, Sauter G, Lykkesfeldt AE, Zapatka M, Radlwimmer B, Lichter P, Tönjes M. The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancer. Oncogene. Nature Publishing Group; 2017 Jul 1;36(29):4124–4134.
39. Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C. Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens. Geburtsh Frauenheilkd. 2017 Jun;77(6):633–644. PMCID: PMC5489401
40. Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, Fasching PA, Fehm T, Gerber B, Janni W, Kühn T, Lüftner D, Möbus V, Müller V, Rody A, Sinn P, Thill M, Thomssen C, Harbeck N, Liedtke C. Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtsh Frauenheilkd. 2017 Jun;77(6):633–644. PMCID: PMC5489401
41. Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, Wasielewski von R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, Sinn P, Sahin U, Bartlett J, Viale G. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Breast Cancer Res. 7 ed. BioMed Central; 2017 May 11;19(1):55. PMCID: PMC5426065
42. Riedel F, Hennigs A, Marme F, Sinn P, Lindel K, Gondos A, Smetanay K, Golatta M, Sohn C, Schutz F, Heil J, Schneeweiss A. Veränderungen in der Anwendung und beim Outcome von Chemotherapie beim frühen Mammakarzinom in der letzten Dekade (2003 – 2014). Senologie. 2017 May 9;14(02):A1–A53.
43. Pfarr N, Penzel R, Endris V, Lier C, Flechtenmacher C, Volckmar A-L, Kirchner M, Budczies J, Leichsenring J, Herpel E, Noske A, Weichert W, Schneeweiss A, Schirmacher P, Sinn P, Stenzinger A. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes Chromosomes Cancer. 2017 Apr;56(4):255–265. PMID: 27792260
44. Sinn P, Schneeweiss A, Endris V, Penzel R, Schirmacher P, Kirchner M, Stenzinger A. Intrinsic subtypes and risk scores in ER+/HER2-Breast Cancer: a comparison of Prosigna and OncotypeDX risk categories with Ki67. Breast. Elsevier; 2017. p. S105.
45. Sinn P, Schneeweiss A, Keller M, Schlombs K, Laible M, Seitz J, Lakis S, Veltrup E, Altevogt P, Eidt S, Wirtz RM, Marme F. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. BMC Cancer. 2017 Feb 13;17(1):124. PMCID: PMC5307758
46. Rüschoff J, Lebeau A, Kreipe H, Sinn P, Gerharz CD, Koch W, Morris S, Ammann J, Untch M, Nicht-interventionelle Untersuchung (NIU) HER2 Study Group. Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany. Mod Pathol. Nature Publishing Group; 2017 Feb;30(2):217–226. PMID: 27767099
47. Blohmer J, Sinn P. 243. Stellungnahme der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) zum Aufruf des Wissenschaftlichen Komitees für Gesundheit, Umwelt und neue Risiken der Europäischen Kommission (SCHEER) zur Sicherheit von PIP-Silikon-Brustimplantaten sowie auch den Zusammenhang zwischen Brustimplantaten und ALCL. Geburtsh Frauenheilkd. 2017;(77):617–619.
48. Rabe T, Schweppe KW et al. Adenomyosis uteri. J Reproduktionsmed Endokrinol. 2017;14(5):211–218.
49. Hennigs A, Riedel F, Marme F, Sinn P, Lindel K, Gondos A, Smetanay K, Golatta M, Sohn C, Schuetz F, Heil J, Schneeweiss A. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat. 4 ed. Springer US; 2016 Dec;160(3):491–499. PMCID: PMC5090013
50. Heil J, Schaefgen B, Sinn P, Richter H, Harcos A, Gomez C, Stieber A, Hennigs A, Rauch G, Schuetz F, Sohn C, Schneeweiss A, Golatta M. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy? Eur J Cancer. Elsevier; 2016 Nov 4;69:142–150. PMID: 27821317
51. Rippinger N, Elsässer M, Sinn P, Sohn C, Fluhr H. Lean Umbilical Cord - a Case Report. Geburtsh Frauenheilkd. 2016 Nov;76(11):1186–1188. PMCID: PMC5123883
52. Abubakar M, Orr N, Daley F, Coulson P, Ali HR, Blows F, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Devilee P, Tollenaar RAEM, Seynaeve C, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, Martens JWM, van Deurzen CHM, investigators K, Bolla MK, Wang Q, Jones M, Schoemaker M, Wesseling J, van Leeuwen FE, van t Veer L, Easton D, Swerdlow AJ, Dowsett M, Pharoah PD, Schmidt MK, García-Closas M. Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. BioMed Central; 2016 Oct 18;18(1):104. PMCID: PMC5070183
53. Denkert C, Stenzinger A, Schem C, Endris V, Klare P, Blohmer J-U, Weichert W, Möbs M, Tesch H, Dietel M, Loi S, Untch M, Minckwitz von G. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget. 2016 Oct 18;7(42):67686–67698. PMCID: PMC5356512
54. Hennigs A, Riedel F, Gondos A, Sinn P, Schirmacher P, Marme F, Jäger D, Kauczor H-U, Stieber A, Lindel K, Debus J, Golatta M, Schütz F, Sohn C, Heil J, Schneeweiss A. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 7 ed. BioMed Central; 2016 Sep 15;16(1):734. PMCID: PMC5024419
55. Sinn P, Helmchen B, Schott S, Löning T. Cervical cancer and its precursor lesions. Der Onkologe. 2016 Aug 29;22(10):737–746.
56. Abubakar M, Howat WJ, Daley F, Zabaglo L, McDuffus L-A, Blows F, Coulson P, Raza Ali H, Benitez J, Milne R, Brenner H, Stegmaier C, Mannermaa A, Chang-Claude J, Rudolph A, Sinn P, Couch FJ, Tollenaar RAEM, Devilee P, Figueroa J, Sherman ME, Lissowska J, Hewitt S, Eccles D, Hooning MJ, Hollestelle A, WM Martens J, HM van Deurzen C, investigators K, Bolla MK, Wang Q, Jones M, Schoemaker M, Broeks A, van Leeuwen FE, Van't Veer L, Swerdlow AJ, Orr N, Dowsett M, Easton D, Schmidt MK, Pharoah PD, García-Closas M. High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. J Pathol Clin Res. 2016 Jul;2(3):138–153. PMCID: PMC4958735
57. Hennigs A, Fuchs V, Sinn P, Riedel F, Rauch G, Smetanay K, Golatta M, Domschke C, Schuetz F, Schneeweiss A, Sohn C, Heil J. Do Patients After Reexcision Due to Involved or Close Margins Have the Same Risk of Local Recurrence as Those After One-Step Breast-Conserving Surgery? Ann Surg Oncol. 2016 Jun;23(6):1831–1837. PMID: 26732272
58. Stefanovic S, Diel I, Sinn P, Englert S, Hennigs A, Mayer C, Schott S, Wallwiener M, Blumenstein M, Golatta M, Heil J, Rom J, Sohn C, Schneeweiss A, Schuetz F, Domschke C. Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment. Ann Surg Oncol. Springer International Publishing; 2016 Mar;23(3):757–766. PMID: 26467455
59. Schaefgen B, Mati M, Sinn HP, Golatta M, Stieber A, Rauch G, Hennigs A, Richter H, Domschke C, Schuetz F, Sohn C, Schneeweiss A, Heil J. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? Ann Surg Oncol. Springer International Publishing; 2016 Mar;23(3):789–795. PMID: 26467456
60. Pfarr N, Sinn P, Klauschen F, Flechtenmacher C, Bockmayr M, Ridinger K, Winterfeld von M, Warth A, Lorenz K, Budczies J, Penzel R, Lennerz JK, Endris V, Weichert W, Stenzinger A. Mutations in genes encoding PI3K-AKT and MAPK signaling define anogenital papillary hidradenoma. Genes Chromosomes Cancer. 2016 Feb;55(2):113–119. PMID: 26493284